Skip to main content
. 2015 Apr 22;79(5):847–859. doi: 10.1111/bcp.12552

Figure 1.

Figure 1

Kaplan−Meier curve showing time to first serious safety warning or removal from market for new active substances: approval through NOC/c vs. priority review. Inline graphic, NOC/c; Inline graphic, priority review. No significant difference between curves, P = 0.5940, log rank (Mantel−Cox) test